Komori
GNI Group (2160) · FactFirst stated

Slower sales growth due to concentrated orders in the pharmaceutical business

First written in FY2021-Q2. . Latest entry: FY2021-Q2.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Growth slowdown due to concentration of pharmaceutical business order timingA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2021-Q2First statedAnnual report

    「売上収益は、当第２四半期連結累計期間は前年同期比で伸びているものの、第１四半期連結累計期間の前年同期比と比較すると鈍化しております。これは、第１四半期に受注が集中したためであります。」

    医薬品事業の売上収益は前年同期比で増加したものの、第1四半期に受注が集中したため、前年同期比の伸びが第1四半期と比べて鈍化した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for GNI Group yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.